CN103191302A - Use of seven medicinal herbs containing radix polygonati officinalis - Google Patents
Use of seven medicinal herbs containing radix polygonati officinalis Download PDFInfo
- Publication number
- CN103191302A CN103191302A CN2013101247774A CN201310124777A CN103191302A CN 103191302 A CN103191302 A CN 103191302A CN 2013101247774 A CN2013101247774 A CN 2013101247774A CN 201310124777 A CN201310124777 A CN 201310124777A CN 103191302 A CN103191302 A CN 103191302A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- rhizoma
- medicinal herbs
- polygonati officinalis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008216 herbs Nutrition 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000016686 tic disease Diseases 0.000 claims abstract description 8
- 239000000796 flavoring agent Substances 0.000 claims description 15
- 235000019634 flavors Nutrition 0.000 claims description 15
- 241000220433 Albizia Species 0.000 claims description 2
- 235000011438 Albizia odoratissima Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 210000004185 liver Anatomy 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 241000842328 Bidens bipinnata Species 0.000 abstract 1
- 240000003271 Leonurus japonicus Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000003390 Chinese drug Substances 0.000 description 32
- 241000700159 Rattus Species 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 238000009835 boiling Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- 238000012856 packing Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005279 excitation period Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a use of seven medicinal herbs containing radix polygonati officinalis in preparation of a medicine for treating liver wind diseases. The seven medicinal herbs containing radix polygonati officinalis include the following material medicines in parts by weight: 13-17 parts of tuber fleeceflower stems, 6-10 parts of cortex albiziae, 3-7 parts of rhizoma acori graminei, 18-22 parts of radix polygonati officinalis, 2-5 parts of tender leonurus japonicus houtt, 3-9 parts of bidens bipinnata and 5-7 parts of rhizoma arisaematis, wherein the liver wind diseases are tic disorder diseases. The use of the seven medicinal herbs containing radix polygonati officinalis has the advantages that the compatibility of the traditional Chinese medicine composition satisfies the assistant and guide rule and can be used for suiting the remedy to the case, so that the effect of treating the liver wind diseases is remarkable. The traditional Chinese medicine composition has the advantages of no toxic and side effect in treatment of the liver wind diseases, low price and the like, and is easily accepted by a patient. Besides, the traditional Chinese medicine composition is less in medicinal herbs, abundant in materials, simple in preparation process and environment-friendly.
Description
Technical field
The present invention relates to the new purposes of Chinese medicine composition, specifically, contain the purposes of Rhizoma Polygonati Odorati seven flavor medicine.
Background technology
Tic disorder be one group with position muscle such as head, limbs and trunk sudden independently do not twitch and (or) the neuropsychiatric disorders disease of the explosive gutturophony of companion and conduct disorder.This year, sickness rate rose to some extent, pathogenic factor may be relevant with heredity, environment, genetic flaw etc., its possible mechanism is relevant with Basal ganglia dopamine (DA) nervous system overacfivity, projects motor cortex and then causes the muscle twitch, projects limbic system and autonomous words and deeds then occur.
Tic disorder belongs to categories such as the traditional Chinese medical science " liver-wind ", " chronic infantile convulsion ", " clonic convulsion ", " tic ", and ancient literature does not have this disease to be discussed specially, sporadically appears among relevant the argumentation." key to therapeutic of children's disease liver have wind very a piece of writing " cloud: " all diseases are new or of a specified duration, all draw liver-wind, and are pneumatic and terminate in the head, and order belongs to liver, and wind is gone into order, up and down as wind, does not gently weigh, and youngster is incompetent, so frequent nictitation also." sick position is mainly liver, in close relations with the heart, lung, spleen, kidney, the basic pathogenesis of generally acknowledging is liver-wind stirring up internally.
Chinese patent literature CN:102000275B discloses a kind of pharmaceutical composition for the treatment of child tic disorder.But the medicine obvious about curative effect, that side effect is low yet there are no report.
Summary of the invention
The objective of the invention is at deficiency of the prior art, provide and contain the purposes of Rhizoma Polygonati Odorati seven flavor medicine in preparation treatment liver-wind disease medicament.
For achieving the above object, the technical scheme that the present invention takes is: contain the purposes of Rhizoma Polygonati Odorati seven flavor medicine in preparation treatment liver-wind disease medicament, described seven flavor medicine is to be made by following bulk drugs: Caulis Polygoni Multiflori 13-17 part, Cortex Albiziae 6-10 part, Rhizoma Acori Graminei 3-7 part, Rhizoma Polygonati Odorati 18-22 part, boy's Herba Leonuri 2-5 part, Herba Bidentis Bipinnatae 3-9 part, Rhizoma Arisaematis 5-7 part, described liver-wind disease is tic disorder disease.
Described seven flavor medicine is to be made by following bulk drugs: Caulis Polygoni Multiflori 14-16 part, Cortex Albiziae 7-9 part, Rhizoma Acori Graminei 3-7 part, Rhizoma Polygonati Odorati 18-22 part, boy's Herba Leonuri 2-5 part, Herba Bidentis Bipinnatae 5-7 part, Rhizoma Arisaematis 5-7 part.
Described seven flavor medicine is to be made by following bulk drugs: 15 parts of Caulis Polygoni Multiflori, 8 parts of Cortex Albiziaes, 5 parts of Rhizoma Acori Graminei, 20 parts of Rhizoma Polygonati Odorati, 3 parts of boy's Herba Leonuris, 6 parts of Herba Bidentis Bipinnatae, 6 parts of Rhizoma Arisaematiss.
The invention has the advantages that:
1, its compatibility of this seven flavor medicine meets Chinese medicine " monarch " principle, suits the remedy to the case, and treatment liver-wind disease effects is obvious;
Advantages such as 2, this seven flavor medicine treatment liver-wind disease has and has no side effect, and price is low are easy to be accepted by the patient;
3, this seven flavor medicine flavour of a drug number is few, abundant raw materials, and preparation technology is simple, and is environmentally friendly, in treatment liver-wind disease good prospects for application arranged.
The specific embodiment
Below the specific embodiment provided by the invention is elaborated.
Embodiment 1
Medication preparation (one)
Caulis Polygoni Multiflori 15 grams, Cortex Albiziae 8 grams, Rhizoma Acori Graminei 5 grams, Rhizoma Polygonati Odorati 20 grams, boy's Herba Leonuri 3 grams, Herba Bidentis Bipinnatae 6 grams, Rhizoma Arisaematis 6 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 2
Medication preparation (two)
Caulis Polygoni Multiflori 13 grams, Cortex Albiziae 6 grams, Rhizoma Acori Graminei 7 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 2 grams, Herba Bidentis Bipinnatae 3 grams, Rhizoma Arisaematis 7 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 3
Medication preparation (three)
Caulis Polygoni Multiflori 17 grams, Cortex Albiziae 10 grams, Rhizoma Acori Graminei 3 grams, Rhizoma Polygonati Odorati 18 grams, boy's Herba Leonuri 5 grams, Herba Bidentis Bipinnatae 9 grams, Rhizoma Arisaematis 5 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 4
Medication preparation (four)
Caulis Polygoni Multiflori 14 grams, Cortex Albiziae 7 grams, Rhizoma Acori Graminei 3 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 2 grams, Herba Bidentis Bipinnatae 7 grams, Rhizoma Arisaematis 5 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 5
Medication preparation (five)
Caulis Polygoni Multiflori 16 grams, Cortex Albiziae 9 grams, Rhizoma Acori Graminei 3 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 2 grams, Herba Bidentis Bipinnatae 5 grams, Rhizoma Arisaematis 7 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 6
Medication preparation (six)
Caulis Polygoni Multiflori 17 grams, Cortex Albiziae 6 grams, Rhizoma Acori Graminei 7 grams, Rhizoma Polygonati Odorati 18 grams, boy's Herba Leonuri 5 grams, Herba Bidentis Bipinnatae 3 grams, Rhizoma Arisaematis 7 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 7
Medication preparation (seven)
Caulis Polygoni Multiflori 13 grams, Cortex Albiziae 10 grams, Rhizoma Acori Graminei 3 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 2 grams, Herba Bidentis Bipinnatae 9 grams, Rhizoma Arisaematis 5 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 8
Medication preparation (eight)
Caulis Polygoni Multiflori 15 grams, Cortex Albiziae 8 grams, Rhizoma Acori Graminei 7 grams, Rhizoma Polygonati Odorati 18 grams, boy's Herba Leonuri 3 grams, Herba Bidentis Bipinnatae 6 grams, Rhizoma Arisaematis 6 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 9
Medication preparation (nine)
Caulis Polygoni Multiflori 15 grams, Cortex Albiziae 8 grams, Rhizoma Acori Graminei 3 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 2 grams, Herba Bidentis Bipinnatae 9 grams, Rhizoma Arisaematis 5 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 10
Medication preparation (ten)
Caulis Polygoni Multiflori 15 grams, Cortex Albiziae 6 grams, Rhizoma Acori Graminei 5 grams, Rhizoma Polygonati Odorati 22 grams, boy's Herba Leonuri 3 grams, Herba Bidentis Bipinnatae 3 grams, Rhizoma Arisaematis 6 gram decocts, adopt automatic medicine boiling packaging machine to decoct packaged pharmaceuticals, every dose of medicine decocts twice continuously, twice decocting liquid is merged be condensed into 100ml, and packing is standby.
Embodiment 11
Pharmacological evaluation
1 experiment material:
Laboratory animal: 60 of cleaning level SD rats, male, body weight 125-135g, the Animal House temperature remains on about 20 ℃, 12 hours dark replacing of illumination in 12 hours.
Medication: laboratory animal is divided into normal control group (10 of rats), model group (10 of rats), Chinese drug-treated group 1(embodiment 2 at random) (10 of rats), Chinese drug-treated group 2(embodiment 3) (10 of rats), Chinese drug-treated group 3(embodiment 4) (10 of rats), Chinese drug-treated group 4(embodiment 1) (10 of rats).Model group and Chinese drug-treated group give APO lumbar injection (2mg/kg), after 3 weeks, model group and Chinese drug-treated group continue to give outside the APO lumbar injection (2mg/kg), model group gives the normal saline of equivalent and irritates stomach, Chinese drug-treated group gavages Chinese medicine, irritate the stomach amount and calculate with reference to the Huang Chinese introduction method that continues, Chinese drug-treated group gives Chinese medicine (10g/kg) and gavages, continuous 4 weeks.The normal control group, except intraperitoneal injection of saline, gives to irritate stomach with the normal saline of Chinese medicine equivalent after 3 weeks with equivalent normal saline lumbar injection.
Irritating the stomach amount calculates with reference to the Huang Chinese introduction method that continues: by non-standard body weight to non-standard body weight:
Db’=?Da’·Sa·Rab·Sb
Db ' expression rat is irritated stomach amount (g/kg) for every kilogram;
Da ' expression child's (20kg) dosage (g/kg);
Sa represents the correction coefficient of the non-standard body weight of child;
Sb represents the correction coefficient of the non-standard body weight of rat;
Rab represent the standard body weight animal by animal a to animal b conversion factor;
Rat is 200g, child 20kg,
Sa=0.669，Sb=0.916，Rab=6.17
2 experimental techniques
2.1 stereotyped behavior experiment
Before the experiment rat was put into the cage endoadaptation 30 minutes, in case the hyperactivity that causes because of new environment, according to shooting be recorded in injection after APO5 minute every record scoring in 5 minutes, scoring every day, standards of grading are as follows: 0 minute and normal saline effect indistinction; Animal heard discontinuously in 1 minute, often with excitation activity; 2 fens animals hear continuously, head has activity slightly, with the periodicity excitation activity; 3 fens animals hear continuously, head movement is many, sting, gnaw, lick action with discontinuous, and of short duration excitation period is arranged; Animal stung continuously, gnaws and licked in 4 minutes, and the no excitation activity phase, whole body is shifted rapidly sometimes.Respectively in pharmaceutical intervention 2 week with 4 weeks the result was compared analysis.
2.2 open wild experiment
In experiment beginning the previous day rat is put into and to be adapted to 3O minute in the experimental box and increase because of the activity that nervous or novel environment cause to get rid of animal, grid number (four claws of Horizontal activity or Crossing Locomotion must drop in the same grid), the upright number of times of rat (Rearing, animal must be stood with metapedes), a reason hair number of times, the fecal grains of passing through with rat level in the blind method observed and recorded 30 minutes.The administration intervention the 1st the week and the 2nd week observed comparative analysis.
2.3 statistical method
Data result is represented with mean scholar standard deviation, adopt the SPSSl6.0 statistical software to carry out statistical procedures, relatively checking with t between two groups wherein, relatively adopt the variance analysis of one factor analysis of variance (one-way ANOVA) and repeated measurement data between many groups, P＜0.05 thinks that difference has statistical significance.
3 results
3.1 modelling verification
In order to verify that the characteristic behavior that liver-wind model (tic disorder) model that APO induces can reproduce liver-wind (tic disorder) changes, before the underway Western medicine intervention, comparison model group and normal group stereotyped behavior scoring, scoring system injection the 1st scoring in 5 minutes after APO5 minute, apparently higher than normal group difference statistical significance (P＜0.05) is arranged by the visible mechanical scoring of model group of table 1, this model group is intervened the observe the curative effect result have credibility, see Table 1.
3.2 stereotyped behavior result of study
3.2.1 pharmaceutical intervention 2 all stereotyped behavior scorings relatively
After treating for 2 weeks, model group scoring and normal group comparing difference have significance (
P＜0.05), model group all is higher than the treatment by Chinese herbs group in the scoring of each time period, wherein the injection APO35 minute after difference have significance (
P＜0.05), see Table 2.
3.2.2 pharmaceutical intervention 4 all stereotyped behavior scorings relatively
After treating for 4 weeks, model group scoring and normal group comparing difference have significance (
P＜0.05), model group all is higher than the treatment by Chinese herbs group in the scoring of each time period, wherein the injection APO15 minute after difference have significance (
P＜0.05), see Table 3.
3.3 open wild experimental studies results
3.3.1 2 weeks of pharmaceutical intervention are opened wild experimental result
Chinese drug-treated group 1, Chinese drug-treated group 2, Chinese drug-treated group 3, Chinese drug-treated group 4 and model group pass through grid number, a reason hair number of times comparing difference have significance (
P＜0.05), see Table 4.
3.3.2 4 weeks of pharmaceutical intervention are opened wild experimental result
Chinese drug-treated group 1, Chinese drug-treated group 2, Chinese drug-treated group 3, Chinese drug-treated group 4 and model group pass through grid number, upright number of times, a reason hair number of times, fecal grains comparing difference have significance (
P＜0.05), see Table 5.
4 experiment conclusion
No matter Chinese medicine composition of the present invention in stereotyped behavior, still has obvious curative effects in opening wild experiment, using clinically has better effect.
Table 1, table 2, table 3, table 4 and table 5 are as follows:
The mechanical scoring of table 1 normal group and model group relatively
| Group | Normal group | Model group |
| N (only) | 10 | 10 |
| 1 week | 0.69±0.32 | 3.10±0.56 * |
| 2 weeks | 0.65±0.33 | 3.35±0.72 * |
| 3 weeks | 0.63±0.31 | 3.41±0.62 * |
Annotate: compare with normal group
( * P＜0.05)
Table 2 pharmaceutical intervention is organized stereotyped behavior relatively 2 Thursdays
| Group | Normal group | Model group | Chinese drug-treated group 1 | Chinese drug-treated group 2 | Chinese drug-treated group 3 | Chinese drug-treated group 4 |
| N (only) | 10 | 10 | 10 | 10 | 10 | 10 |
| 5-10min | 0.53±0.36 | 3.50±0.67 | 3.20±0.76 | 2.90±0.63 | 2.95±0.58 | 2.90±0.63 |
| 15-20min | 0.58±0.39 | 3.00±0.76 | 2.80±0.69 | 2.30±0.69 | 2.85±0.54 | 2.20±0.69 |
| 25-30min | 0.78±0.37 | 2.95±0.49 | 2.15±0.91 | 2.20±0.56 | 2.10±0.63 | 2.20±0.46 |
| 35-40min | 0.57±0.33 | 2.60±0.67 | 1.30±0.68 * | 1.15±0.57 * | 1.25±0.32 * | 1.05±0.47 * |
| 45-50min | 0.61±0.29 | 1.60±0.79 | 0.90±0.45 | 0.9±0.25 * | 0.85±0.14 | 0.8±0.25 * |
| 55-60min | 0.44±0.35 | 1.20±0.42 | 0.65±0.34 * | 0.66±0.26 * | 0.76±0.31 * | 0.46±0.36 * |
Annotate: compare with model group
( * P＜0.05)
Table 3 pharmaceutical intervention is organized stereotyped behavior relatively 4 Thursdays
| Group | Normal group | Model group | Chinese drug-treated group 1 | Chinese drug-treated group 2 | Chinese drug-treated group 3 | Chinese drug-treated group 4 |
| N (only) | 10 | 10 | 10 | 10 | 10 | 10 |
| 5-10min | 0.57±0.33 | 3.30±0.48 | 2.60±0.69 | 2.70±0.51 | 2.70±0.63 | 2.50±0.51 |
| 15-20min | 0.67±0.37 | 3.40±0.69 | 2.40±0.82 * | 2.30±0.63 * | 2.35±0.54 * | 2.30±0.53 * |
| 25-30min | 0.54±0.42 | 3.20±0.42 | 1.85±0.63 * | 1.90±0.63 * | 1.75±0.57 * | 1.80±0.63 * |
| 35-40min | 0.61±0.29 | 2.30±0.74 | 1.05±0.25 * | 0.95±0.15 * | 1.15±0.28 * | 0.85±0.12 * |
| 45-50min | 0.65±0.24 | 1.70±0.82 | 0.95±0.24 | 0.75±0.33 * | 0.85±0.33 | 0.55±0.43 * |
| 55-60min | 0.49±0.39 | 1.30±0.48 | 0.60±0.51 * | 0.65±0.28 * | 0.73±0.31 * | 0.45±0.28 * |
Annotate: compare with model group
( * P＜0.05)
Open wild experimental result in 2 weeks of table 4 pharmaceutical intervention relatively
| Group | Normal group | Model group | Chinese drug-treated group 1 | Chinese drug-treated group 2 | Chinese drug-treated group 3 | Chinese drug-treated group 4 |
| N (only) | 10 | 10 | 10 | 10 | 10 | 10 |
| Pass through the grid number | 10.50±2.06 | 802.60±54.86 | 410.90±92.35 * | 350.60±150.03 * | 395.00±111.07 * | 365.60±150.03 * |
| Upright number of times | 2.30±0.94 | 8.20±2.09 | 7.55±1.43 | 7.430±1.50 | 7.90±1.47 | 7.20±1.50 |
| Reason hair number of times | 7.90±1.91 | 2.30±1.05 | 4.46±1.26 * | 4.00±1.98 * | 4.10±1.31 * | 4.10±1.78 * |
| Fecal grains | 3.00±1.15 | 7.20±1.81 | 4.50±1.89 * | 4.80±1.52 | 4.90±1.49 * | 4.60±1.52 |
Annotate: compare with model group
( * P＜0.05)
Open wild experimental result in 4 weeks of table 5 pharmaceutical intervention relatively
| Group | Normal group | Model group | Chinese drug-treated group 1 | Chinese drug-treated group 2 | Chinese drug-treated group 3 | Chinese drug-treated group 4 |
| N (only) | 10 | 10 | 10 | 10 | 10 | 10 |
| Pass through the grid number | 11.10±3.60 | 795.60±122.23 | 351.50±73.46 * | 334.80±160.41 * | 371.90±92.09 * | 331.50±73.46 * |
| Upright number of times | 2.20±0.78 | 8.90±2.18 | 5.57±2.01 * | 5.90±1.98 * | 5.40±1.83 * | 5.40±2.01 * |
| Reason hair number of times | 8.10±2.02 | 2.20±0.91 | 5.18±1.85 * | 5.10±2.12 * | 4.90±1.79 * | 5.10±1.05 * |
| Fecal grains | 2.90±1.19 | 7.40±1.89 | 4.10±1.47 * | 4.60±1.71 * | 4.10±1.85 * | 4.10±1.47 * |
Annotate: compare with model group
( * P＜0.05)
Claims (3)
1. contain the purposes of Rhizoma Polygonati Odorati seven flavor medicine in preparation treatment liver-wind disease medicament, it is characterized in that, described seven flavor medicine is to be made by following bulk drugs: Caulis Polygoni Multiflori 13-17 part, Cortex Albiziae 6-10 part, Rhizoma Acori Graminei 3-7 part, Rhizoma Polygonati Odorati 18-22 part, boy's Herba Leonuri 2-5 part, Herba Bidentis Bipinnatae 3-9 part, Rhizoma Arisaematis 5-7 part, described liver-wind disease is tic disorder disease.
2. purposes according to claim 1, it is characterized in that described seven flavor medicine is to be made by following bulk drugs: Caulis Polygoni Multiflori 14-16 part, Cortex Albiziae 7-9 part, Rhizoma Acori Graminei 3-7 part, Rhizoma Polygonati Odorati 18-22 part, boy's Herba Leonuri 2-5 part, Herba Bidentis Bipinnatae 5-7 part, Rhizoma Arisaematis 5-7 part.
3. purposes according to claim 1 is characterized in that, described seven flavor medicine is to be made by following bulk drugs: 15 parts of Caulis Polygoni Multiflori, 8 parts of Cortex Albiziaes, 5 parts of Rhizoma Acori Graminei, 20 parts of Rhizoma Polygonati Odorati, 3 parts of boy's Herba Leonuris, 6 parts of Herba Bidentis Bipinnatae, 6 parts of Rhizoma Arisaematiss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101247774A CN103191302A (en) | 2013-04-11 | 2013-04-11 | Use of seven medicinal herbs containing radix polygonati officinalis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101247774A CN103191302A (en) | 2013-04-11 | 2013-04-11 | Use of seven medicinal herbs containing radix polygonati officinalis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103191302A true CN103191302A (en) | 2013-07-10 |
Family
ID=48714236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101247774A Pending CN103191302A (en) | 2013-04-11 | 2013-04-11 | Use of seven medicinal herbs containing radix polygonati officinalis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191302A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1456248A (en) * | 2003-02-18 | 2003-11-19 | 毛友昌 | Preparing method for nourishing blood and tranquilization tablet |
| CN101134082A (en) * | 2007-09-14 | 2008-03-05 | 尹克华 | Traditional Chinese medicine for treating early hemorrhagic stroke |
| CN102008643A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Mixture for treating panasthenia |
| CN102008644A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Drug for treating neurasthenia and application thereof |
| CN102552827A (en) * | 2012-03-13 | 2012-07-11 | 申娟 | Medicine for treating epilepsy |
-
2013
- 2013-04-11 CN CN2013101247774A patent/CN103191302A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1456248A (en) * | 2003-02-18 | 2003-11-19 | 毛友昌 | Preparing method for nourishing blood and tranquilization tablet |
| CN101134082A (en) * | 2007-09-14 | 2008-03-05 | 尹克华 | Traditional Chinese medicine for treating early hemorrhagic stroke |
| CN102008643A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Mixture for treating panasthenia |
| CN102008644A (en) * | 2010-12-09 | 2011-04-13 | 上海市精神卫生中心 | Drug for treating neurasthenia and application thereof |
| CN102552827A (en) * | 2012-03-13 | 2012-07-11 | 申娟 | Medicine for treating epilepsy |
Non-Patent Citations (1)
| Title |
|---|
| 沈映君: "《中药药理学》", 31 December 1997, 上海科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115429864B (en) | Traditional Chinese medicine composition for treating depression | |
| CN105725211A (en) | Food health product for improving sleep and preparation method thereof | |
| CN101711810A (en) | Preparation used for improving sleep and enhancing immunity | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN107126510A (en) | A kind of Chinese medicine composition for treating child tic disorder syndrome and its application | |
| CN102727858A (en) | Medical composition for treating headaches and migraine, preparation method and application thereof | |
| CN103251757B (en) | Borneol-containing compound preparation as well as preparation method and application thereof | |
| CN112717068B (en) | Traditional Chinese medicine composition for treating chronic fatigue syndrome and application thereof | |
| CN103191302A (en) | Use of seven medicinal herbs containing radix polygonati officinalis | |
| CN101129633A (en) | Medicament for treating neurasthenia and preparation method thereof | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN103169874A (en) | Use of traditional Chinese medicine composition containing cortex albiziae | |
| CN103169872A (en) | Application of traditional Chinese medicine composition | |
| CN114632129A (en) | Traditional Chinese medicine for treating cough variant asthma in children and preparation method thereof | |
| CN103169873A (en) | Effective medicament for treating liver wind | |
| CN101664441A (en) | Traditional Chinese medicine composition containing isatis leaf and application thereof | |
| CN103169871A (en) | Medicament for treating tic disorder disease | |
| CN104225201A (en) | Medicinal composition for treating cough | |
| CN112641912A (en) | Medicine for quickly treating attention deficit hyperactivity disorder | |
| CN103169878A (en) | Application of gastrodia elata in pharmacy | |
| CN113244204B (en) | Application of zingiberenone A in preparation and/or application of zingiberenone A as product for enhancing body immunity | |
| CN105055694B (en) | A kind of traditional Chinese medicine preparation for the treatment of depression caused by liver stagnation and turning into fire | |
| CN116077563B (en) | Traditional Chinese medicine composition for treating liver and kidney deficiency type depression and preparation method thereof | |
| CN103006988B (en) | Traditional Chinese medicine composition for treating tourette syndrome | |
| CN100435817C (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130710 |